Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 5—May 2022

Multisystem Inflammatory Syndrome in Children after SARS-CoV-2 Vaccination

Eisha Jain, Jeffrey R. Donowitz, Elizabeth Aarons, Beth C. Marshall, and Michael P. MillerComments to Author 
Author affiliations: Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA (E. Jain); Children’s Hospital of Richmond at Virginia Commonwealth University, Richmond (J.R. Donowitz, E. Aarons, B.C. Marshall, M.P. Miller)

Cite This Article


Multisystem inflammatory syndrome in children (MIS-C) is a hyperinflammatory state that occurs after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We present 2 cases of MIS-C after SARS-CoV-2 vaccination; 1 patient had evidence of recent SARS-CoV-2 infection. Our findings suggest that vaccination modulates the pathogenesis of MIS-C.

Multisystem inflammatory syndrome in children (MIS-C) was first described in 2020 during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic (1). MIS-C is a systemic hyperinflammatory state necessitating hospitalization in patients <21 years of age who experienced >24 hours of fever, recent SARS-CoV-2 exposure or positive testing, involvement of >2 organ systems, and >1 of the following laboratory results: elevated C-reactive protein (CRP), erythrocyte sedimentation rate, fibrinogen, procalcitonin, D-dimer, ferritin, lactate dehydrogenase, interleukin-6, neutrophils, reduced lymphocytes, or reduced albumin (2). It is unknown whether vaccination can precipitate or abrogate MIS-C and whether natural infection preceding or at the time of vaccination plays a role (1). We describe MIS-C in 2 adolescents recently vaccinated with BNT162b2 (Pfizer-BioNTech, and raise the possibility of vaccination modulating MIS-C pathogenesis.

The Study

Patient 1 was a 15-year-old girl with asthma who received her first dose of BNT162b2 6 days before seeking care. She had low-grade fever and myalgia, which resolved within 2 days of vaccination. Four days later, she experienced 102°F fevers, headaches, nonbilious emesis, myalgias, chest pain, and a rash. Emergency department (ED) examination identified pharyngeal erythema, bilateral conjunctivitis, and a diffuse blanching rash. She had no respiratory or cardiovascular symptoms. At admission, laboratory test results showed leukocytosis with polymorphonuclear cell predominance and elevated CRP, fibrinogen, prothrombin time, brain natriuretic peptide (BNP), and D-dimer (Table). Urinalysis revealed trace protein, large blood, moderate leukocyte esterase, 10–20 leukocytes per high-powered field, and 1+ bacteria. Results of nasopharyngeal SARS-CoV-2 reverse transcription PCR were negative. Further tests included chest radiograph, chest computed tomography angiography, electrocardiogram, and echocardiogram; all results were unremarkable. She was admitted to the pediatric intensive care unit (ICU) and given 2 g/kg intravenous immune globulin (IVIG) for suspected of MIS-C. Symptoms rapidly improved. Leukocyte level decreased to 11.0 K/uL and D-dimer to 2.5 mg/L within 48 hours. The patient remained hemodynamically stable throughout admission and was afebrile with improved symptoms when she was discharged 3 days after admission. SARS-CoV-2 antibody test results at discharge were positive for nucleocapsid but negative for spike. Two days after discharge, the patient returned to the ED for throbbing headaches, nausea, and fatigue. CRP had downtrended since discharge to 2.71 mg/L. Magnetic resonance venography results were normal and she was discharged on antimigraine medication.

Patient 2 was a previously healthy female 17-year-old who received her first dose of BNT162b2 vaccination 7 days before seeking care. Three days after vaccination, she experienced fevers, headaches, abdominal pain, fatigue, and myalgias. Her primary care provider noted leukocytosis to 20 K/uL and referred her to the ED. She had a 103.1°F fever, diffuse abdominal tenderness, and costovertebral angle tenderness. She had no respiratory symptoms. At admission, laboratory test results showed leukocytosis with polymorphonuclear cell predominance and elevated CRP, erythrocyte sedimentation rate, lactate dehydrogenase, BNP, troponin, D-dimer, creatinine, aspartate aminotransferase, and alkaline phosphate (Table). Urinalysis revealed 100 mg/dL protein, moderate blood, moderate leukocyte esterase, 10–20 leukocytes per high-powered field, 5–10 red blood cells per high powered field, and no bacteria. Urine culture was positive for 10,000 CFU/mL of Escherichia coli. Blood culture results were negative. Electrocardiogram showed sinus tachycardia and nonspecific T-wave abnormalities. Abdomen and pelvis computed tomography showed diffuse left renal enlargement without hypoattenuation or hyperattenuation and possible polycystic ovaries. Results of chest radiograph and echocardiogram were normal. Nasopharyngeal SARS-CoV-2 RT-PCR was negative. Results of SARS-CoV-2 spike antibody testing were positive; nucleocapsid antibody testing was not performed. She started 3 days of intravenous methylprednisolone (30 mg 2×/d) and 1 day IVIG (2 g/kg) for MIS-C. Troponin decreased to <0.05 within 24 hours and CRP to 16.2 within 48 hours. BNP rose to 2,024 on hospital day 2. Repeat echocardiogram showed mild right coronary artery ectasia, and she was started on 325 mg of aspirin daily. On hospital day 3, repeat echocardiogram results were normal, and she was afebrile. Aspirin was decreased to 81 mg daily. She was discharged on hospital day 4 with no fevers for 60 hours and downtrending inflammatory markers including CRP to 8.49 mg/dL. She was also treated for a possible UTI.


This report describes 2 cases of MIS-C within 1 week of receiving the first dose of BNT162b2. There is no specific test for MIS-C; although both patients met diagnostic criteria, alternative diagnoses were possible. Patient 2 had costovertebral angle tenderness, unilateral renal enlargement, and 10,000 CFU/mL growth of a uropathogen on culture. Given the low level of bacterial growth, lack of enhancement on her CT, and constellation of lab and imaging abnormalities not commonly seen with urinary tract infections, MIS-C remains her most likely diagnosis.

Patient 1 had a positive antinucleocapsid antibody suggesting community-acquired COVID-19 infection before MIS-C developed (P.D. Burbelo et al., unpub. data, Salzman et al. describe 3 similar cases in which MIS or an MIS-like illness developed after COVID-19 vaccination, particularly in the setting of community-acquired COVID-19 (3). The chronology of events in these cases raises the possibility that vaccination may be involved in the pathogenesis of MIS-C when preceded by community-acquired SARS-CoV-2.

The pathogenesis of MIS-C is thought to involve immune dysregulation and hyperinflammation (4). Studies have identified high levels of receptor-binding protein (RBD) antibodies in children with severe MIS-C (5,6). Both natural SARS-CoV-2 infection and BNT162b2 vaccination have been shown to elicit RBD antibodies (7). It may be possible that the immune responses to these 2 forms of exposure to SARS-CoV-2 interact to shape the manifestations of mild MIS-C in the postinfectious period of COVID-19. Although both of these cases were mild, we have insufficient data on the pathogenesis of MIS-C to understand how vaccination may shape symptomatology.

A recent report by Zambrano et al. documented that 61/97 (62.9%) MIS-C cases in unvaccinated patients required ICU admission (8). That report had a small number of vaccinated cases; 1 in 5 of those vaccinated needed ICU care (8). An analysis of postvaccination MIS-C in 21 patients showed that 3 (14%) required invasive mechanical ventilation, 8 (38%) required vasopressors, and 12 (57%) required ICU care (A.R. Yousaf et al., unpub. data, In contrast to Zambrano et al.’s vaccinated cases and our reported cases, the Yousaf et al. report suggests a similar number of ICU admissions in vaccinated and unvaccinated persons.

Studies have shown that COVID-19 vaccination is associated with reduced incidence of MIS-C, especially if 2 doses are given. A study of MIS-C cases in France during September–October 2021 found a significantly lower risk of MIS-C among vaccinated adolescents than those who were unvaccinated (9). Zambrano et al. found a 91% protective effect of complete (2 doses) BNT162b2 vaccination against MIS-C (8). Phase 2 and phase 3 clinical trials of BNT162b2 revealed 0 cases of MIS-C after vaccination (10). Despite the reports of postvaccination MIS-C, vaccination clearly lowers the overall MIS-C burden, probably by preventing infection. These studies also suggest low likelihood of vaccination triggering development of MIS-C.

If vaccination can play a role in MIS-C pathogenesis, it is likely an extremely rare event and may involve an underlying genetic predisposition or be contingent on extraneous factors like recent SARS-CoV-2 community exposure. Our findings in 2 cases of MIS-C within 1 week of a dose of BNT162b2 raise the possibility that vaccination may alter the symptom profile of MIS-C.

Ms. Jain is a third-year medical student at the Virginia Commonwealth University School of Medicine in Richmond, Virginia. Her primary research interests include infectious disease and pediatric medicine.



  1. Ahmed  M, Advani  S, Moreira  A, Zoretic  S, Martinez  J, Chorath  K, et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine. 2020;26:100527. DOIPubMedGoogle Scholar
  2. Centers for Disease Control and Prevention. Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C). February 11, 2020 [cited 2021 Oct 1].
  3. Salzman  MB, Huang  C-W, O’Brien  CM, Castillo  RD. Multisystem inflammatory syndrome after SARS-CoV-2 infection and COVID-19 vaccination. Emerg Infect Dis. 2021;27:19448. DOIPubMedGoogle Scholar
  4. Nakra  NA, Blumberg  DA, Herrera-Guerra  A, Lakshminrusimha  S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children (Basel). 2020;7:69. DOIPubMedGoogle Scholar
  5. Rostad  CA, Chahroudi  A, Mantus  G, Lapp  SA, Teherani  M, Macoy  L, et al. Quantitative SARS-CoV-2 serology in children with multisystem inflammatory syndrome (MIS-C). Pediatrics. 2020;146:e2020018242. DOIPubMedGoogle Scholar
  6. Yonker  LM, Neilan  AM, Bartsch  Y, Patel  AB, Regan  J, Arya  P, et al. Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): clinical presentation, infectivity, and immune responses. J Pediatr. 2020;227:4552.e5. DOIPubMedGoogle Scholar
  7. Trougakos  IP, Terpos  E, Zirou  C, Sklirou  AD, Apostolakou  F, Gumeni  S, et al. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med. 2021;19:208. DOIPubMedGoogle Scholar
  8. Zambrano  LD, Newhams  MM, Olson  SM, Halasa  NB, Price  AM, Boom  JA, et al.; Overcoming COVID-19 Investigators. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 years—United States, July–December 2021. MMWR Morb Mortal Wkly Rep. 2022;71:528. DOIPubMedGoogle Scholar
  9. Levy  M, Recher  M, Hubert  H, Javouhey  E, Fléchelles  O, Leteurtre  S, et al. Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France. JAMA. 2022;327:2813. DOIPubMedGoogle Scholar
  10. Food and Drug Administration; Vaccines and Related Biological Products Advisory Committee. VRBPAC briefing document, October 26, 2021 [cited 2022 Feb 28].




Cite This Article

DOI: 10.3201/eid2805.212418

Original Publication Date: March 11, 2022

Table of Contents – Volume 28, Number 5—May 2022

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Michael P. Miller, Children’s Hospital of Richmond at Virginia Commonwealth University, 5801 Bremo Rd, Richmond, VA 23226, USA

Send To

10000 character(s) remaining.


Page created: March 01, 2022
Page updated: April 19, 2022
Page reviewed: April 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.